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Anti-CD63 antibodies suppress 
IgE-dependent allergic reactions 
in vitro and in vivo
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High-affinity IgE receptor (Fc
 
 
 
RI) cross-linking on mast cells (MCs) induces secretion of 
preformed allergy mediators (degranulation) and synthesis of lipid mediators and cytokines. 
Degranulation produces many symptoms of immediate-type allergic reactions and is 
modulated by adhesion to surfaces coated with specific extracellular matrix (ECM) proteins. 
The signals involved in this modulation are mostly unknown and their contribution to allergic 
reactions in vivo is unclear. Here we report the generation of monoclonal antibodies that 
potently suppress Fc
 
 
 
RI-induced degranulation, but not leukotriene synthesis. We identified 
the antibody target as the tetraspanin CD63. Tetraspanins are membrane molecules that 
form multimolecular complexes with a broad array of molecules including ECM protein-
binding 
 
 
 
 integrins. We found that anti-CD63 inhibits MC adhesion to fibronectin and 
vitronectin. Furthermore, anti-CD63 inhibits Fc
 
 
 
RI-mediated degranulation in cells adherent 
to those ECM proteins but not in nonadherent cells. Thus the inhibition of degranulation by 
anti-CD63 correlates with its effect on adhesion. In support of a mechanistic linkage 
between the two types of inhibition, anti-CD63 had no effect on Fc
 
 
 
RI-induced global 
tyrosine phosphorylation and calcium mobilization but impaired the Gab2–PI3K pathway that 
is known to be essential for both degranulation and adhesion. Finally, we showed that these 
antibodies inhibited Fc
 
 
 
RI-mediated allergic reactions in vivo. These properties raise the 
possibility that anti-CD63 could be used as therapeutic agents in MC-dependent diseases.
 
Mast cells (MCs) are important effectors of
immediate-type allergic responses and play a
role in host defense and autoimmune diseases
(1–4). Activated MCs adhere to extracellular
matrix (ECM) proteins such as fibronectin,
vitronectin, and laminin (5, 6) that bind to
integrin adhesion molecules. MCs express var-
ious integrins (e.g., VLA-4 
 
 
 
4
 
 
 
1, VLA-5
 
 
 
5
 
 
 
1, the vitronectin receptor 
 
 
 
v
 
 
 
3). Adhe-
sion is enhanced by activation of cell surface
receptors such as c-Kit or Fc
 
 
 
RI (7, 8). In
turn, MC adhesion to ECM proteins amplifies
Fc
 
 
 
RI-induced secretion (9, 10). Antibodies
recognizing the integrins 
 
 
 
4
 
 
 
1, 
 
 
 
5
 
 
 
1, and
 
 
 
v
 
 
 
3 suppress MC degranulation. Used in
combination, they suppress anaphylaxis (11).
The signaling cascade triggered upon Fc
 
 
 
RI
cross-linking is induced by the activation of
protein–tyrosine kinases (PTK) of the Src
family, such as Lyn, which phosphorylates the
intracellular immunoreceptor tyrosine-based
activation motifs (ITAMs) present in the 
 
 
 
 and
 
 
 
 chains of Fc
 
 
 
RI (12). Signaling molecules
bearing SH2 domains then bind these phos-
phorylated ITAMs, leading to the formation of
associated multiprotein complexes. The path-
way controlled by Lyn leads to the formation
of a signaling complex organized around the
LAT adaptor involving Vav, SLP-76, Grb2-Sos-
Ras, PLC
 
 
 
, and phosphatidylinositol-3 kinase
(PI3K). An essential molecule in the forma-
tion of these complexes is the PTK Syk, which
phosphorylates and activates multiple mole-
cules downstream. This pathway induces cal-
cium (Ca
 
2
 
 
 
) mobilization and putatively reg-
ulates degranulation via the Ca
 
2
 
 
 
-dependent
PKC
 
 
 
. Downstream of Syk activation, the
MAP kinase pathway leads to phospholipase
A2 activation, an initial step in the production
of arachidonic acid metabolites such as leu-
kotriene C4 (LTC4) and prostaglandin D2
(13–15). A second signaling pathway leading
to degranulation has been identified (16). It is
initiated by the Fyn PTK. Fyn activation
promotes the formation of a signaling com-
plex organized around the Gab2 adaptor (17),
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which contains SHP-2 and a PI3K. PI3K activation in this
complex provides a Ca
 
2
 
 
 
-independent signal for degranula-
tion by subsequent activation of PDK-1 and the Ca
 
2
 
 
 
-inde-
pendent protein kinase C-
 
 
 
 (PKC
 
 
 
).
Several inhibitory receptors suppress Fc
 
 
 
RI-induced MC
functions. They include the MC function–associated mole-
cule MAFA, gp49BI, Fc
 
 
 
RIIB, and the paired immunoglob-
ulin-like receptor PIR-B (18). All possess an intracellular in-
hibitory signaling motif, the immunoreceptor tyrosine-based
inhibition motif ITIM. Upon activation, ITIM phosphoryla-
tion leads to the recruitment and activation of tyrosine phos-
phatases such as SHP-1, or inositol phosphatases such as
SHIP, which suppress signaling in its early stages.
Inhibition of Fc
 
 
 
RI-dependent MC degranulation by
antibodies directed against tetraspanins has been reported,
but the mechanism is not known. Our laboratory has de-
scribed a mAb against CD81 that suppresses MC degranula-
tion (19). Another mAb directed against the rat AD1 antigen
was also reported to inhibit Fc
 
 
 
RI-induced degranulation
moderately (20). It was shown later that this mAb recognizes
the CD63 molecule that belongs to the tetraspanin family
(21). No additional data clarifying its role in MCs have been
published since then. Tetraspanins (or transmembrane-4 su-
perfamily proteins) comprise a large family of proteins (22,
23) that are not known to have extracellular ligands. They
form membrane complexes by lateral interactions with other
tetraspanins and other molecules such as 
 
 
 
 integrins. Tet-
raspanins may regulate integrin functions by interfering with
integrin signaling, localization, or trafficking (23, 24). CD63
interacts with the 
 
 
 
3, 
 
 
 
4, and 
 
 
 
6 chains of 
 
 
 
1 integrins (25,
26) and modulates adhesion (27). Given our current knowl-
edge about tetraspanins in cell migration and adhesion, these
molecules may play a similar role in MC biology. However,
their role in MCs has not been studied extensively.
In this study, we have generated mAbs against rat baso-
philic leukemia (RBL)-2H3 cells. These mAbs potently sup-
press Fc
 
 
 
RI-induced MC degranulation in vitro and allergic
reactions in vivo. We have identified the antibody target as
the CD63 tetraspanin. Anti-CD63 mAbs are able to suppress
both adhesion to vitronectin and fibronectin and degranula-
tion of MC grown on these substrates. Furthermore, we
show that anti-CD63 specifically suppresses degranulation
and Gab2-dependent signaling such as PKC
 
 
 
 activation, in
adherent cells, but not in nonadherent cells.
 
RESULTS
Generation and characterization of mAbs inhibiting Fc
 
 
 
RI-
dependent MC degranulation
 
To identify membrane proteins capable of modulating
Fc
 
 
 
RI-dependent effector functions, we produced mAbs
against RBL-2H3 cells, a well-characterized MC model.
The mAbs 7A6 and 12A10 were identified as potent sup-
 
Figure 1. mAb 12A10 suppresses Fc
 
 
 
RI-induced serotonin release, 
but does not inhibit LTC4 production.
 
 (A) Serotonin release from RBL-2H3 
cells loaded with 0.2 
 
 
 
g/ml anti-DNP IgE and stimulated with DNP-HSA 
(DNP; 50 ng/ml) to induce Fc
 
 
 
RI cross-linking or with vehicle (nil) for 30 
min. Results are expressed as percentage of total serotonin uptake (mean 
 
  
 
SEM of five experiments in duplicate). The two columns on the left are
for cells without mAb preincubation. The four columns on the right are for 
cells preincubated with IgG1 control or 12A10 mAb (2 
 
 
 
g/ml) for 30 min 
before Fc
 
 
 
RI triggering. (B) Dose response of inhibition of Fc
 
 
 
RI-induced 
serotonin release by 12A10 or IgG1 control. Cells were triggered as in A. 
Results are expressed as mean
 
   
 
SEM of four experiments with duplicate 
samples. ** P 
 
  
 
0.0117. (C) LTC4 production induced by Fc
 
 
 
RI aggregation 
(50 ng/ml DNP-HSA for 20 min) in RBL-2H3 cells preincubated with 
10 
 
 
 
g/ml of IgG1 or 12A10 (mean
 
 
 
 SEM of two experiments in triplicate; 
P 
 
  
 
0.7532). 
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pressors of Fc
 
 
 
RI-induced degranulation, as determined
by serotonin release in adherent RBL-2H3 cells. Fig. 1 A
shows that preincubation with the 12A10 mAb at 2 
 
 
 
g/
ml had a significant suppressive effect on degranulation (P 
 
 
 
0.0051). At this concentration, Fc
 
 
 
RI-induced degranula-
tion in 12A10-treated cells was inhibited by 47% compared
with IgG1-treated cells. Dose response experiments showed
that a 12A10 concentration of 1 
 
 
 
g/ml already resulted in
significant suppression of Fc
 
 
 
RI-induced serotonin release,
with near-maximal inhibition occurring at 10 
 
 
 
g/ml (Fig. 1
B). Similar data were obtained using the 7A6 mAb (unpublished
data). We then investigated whether other MC functions
such as production of arachidonic acid metabolites were af-
fected by these mAbs. In contrast to serotonin, which is
stored in preformed granules and released upon MC activa-
tion, arachidonic acid metabolites are synthesized de novo
and secreted upon MC activation. In addition, some late sig-
nals required for both events are different, with degranula-
tion being mainly dependent on Fc
 
 
 
RI-induced PKC ac-
tivation and arachidonic acid metabolites being mainly
dependent on MAP kinase-induced phospholipase A2 acti-
vation (13, 15, 16, 28). Fig. 1 C shows that LTC4 produc-
tion after Fc
 
 
 
RI cross-linking for 20 min was not signifi-
cantly affected by 12A10 preincubation. These data show
that these mAbs selectively suppress serotonin release, with-
out affecting synthesis of lipid mediators.
 
Identification of the antibody target as CD63
 
We next identified the molecule(s) recognized by these in-
hibitory mAbs. Immunoprecipitation with one of the mAbs
followed by immunoblotting with either one showed that
both mAbs recognized the same 50–60-kD molecule(s) (Fig.
2 A and unpublished data). Cross-competition experiments
using excess of one unlabeled mAb to block binding of the
other FITC-labeled mAb followed by flow cytometric anal-
ysis demonstrated that both 7A6 and 12A10 mAbs bound to
the same or adjacent epitopes (unpublished data). The target
molecule was found to be heavily 
 
N
 
-glycosylated (
 
 
 
50%), as
treatment with 
 
N
 
-glycanase yielded a sharp band at 25 kD in
immunoblots (unpublished data). The antibodies recognize
the protein only in its nonreduced form. As CD63 possesses
properties similar to these, we tested whether these mAbs
recognize CD63. We took advantage of an Ab directed
against the AD1 antigen, which recognizes CD63 (20, 21).
Immunoprecipitation and blotting of RBL cell lysates with
anti-AD1 identified a 50–60-kD protein similar to that iden-
tified by 12A10 (Fig. 2 A, left). Immunoprecipitation with
12A10 and blotting with anti-AD1, and the converse, ap-
peared to detect the same protein as that identified by
anti-AD1 (Fig. 2 A). These experiments suggested that the
molecule recognized by 12A10 and 7A6 was rat CD63. To
confirm this, we cloned the cDNA for rat CD63 from RBL-
2H3 cDNA and expressed it in the human cell line U937.
Note that 12A10 and 7A6 do not recognize human or
mouse CD63. Cells stably transfected with a FLAG-tagged
form of CD63 were tested for reactivity with 12A10 and
7A6. Immunoprecipitation with 12A10 yielded a band of
the expected size in transfected cells, but not in untrans-
fected cells (Fig. 2 B, top). Similar results were obtained by
immunoprecipitating with anti-FLAG and blotting with
Figure 2. The inhibitory 7A6 and 12A10 mAbs recognize rat CD63. 
(A) RBL cell lysates were immunoprecipitated with 12A10, an anti-rat 
CD63 antibody (AD1), or isotype control (IgG1), and immunoblotted with 
either AD1 or 12A10 mAb. (B, top) Lysates from WT U937 cells and from 
U937 cells stably transfected with rat CD63 were immunoprecipitated 
with 12A10 or isotype control and immunoblotted with 12A10 mAb. 
(B, bottom) WT U937 cells and U937 cells stably transfected with rat CD63 
were incubated with 7A6 or control isotype followed by FITC–anti-mouse 
and analyzed by flow cytometry. 
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12A10 (unpublished data). Staining with 7A6 and analysis by
flow cytometry showed that 7A6, but not an isotype control,
reacted with the cell surface of CD63-transfected cells, and
not with untransfected cells (Fig. 2 B, bottom). Thus, we
concluded that the antigen recognized by 7A6 and 12A10 is
the tetraspanin CD63.
 
Anti-CD63 inhibits MC adhesion to fibronectin and 
vitronectin and potently suppresses degranulation 
of adherent MCs
 
We next investigated the relationship between CD63 and
MC adhesion and degranulation. CD63 interacts with the
 
 
 
3, 
 
 
 
4, and 
 
 
 
6 chains of 
 
 
 
1 integrins and is involved in 
 
 
 
1
integrin function (25–27). Adhesion of MCs to surfaces
coated with the 
 
 
 
1 integrin substrate fibronectin enhances
Fc
 
 
 
RI aggregation induced degranulation (9, 10). In addi-
tion, RBL-2H3 cells adhere to fibronectin, vitronectin and
fibrinogen, and antibodies against the fibronectin- and vi-
tronectin-binding integrins 
 
 
 
4
 
 
 
1, 
 
 
 
5
 
 
 
1, and 
 
 
 
v
 
 
 
3 inhibit
degranulation and anaphylaxis (11). To test a possible link
between degranulation and adhesion in the effect of anti-
CD63 on MC, we assessed whether the inhibitory effect of
anti-CD63 on degranulation observed with adherent cells
was detected in cells stimulated in suspension. Cells were
loaded with anti-DNP IgE and [
 
3
 
H]serotonin. They were
next either detached and maintained in suspension, or left
adherent. Both samples were preincubated with anti-CD63
or isotype control (4 
 
 
 
g/ml). Cells were then triggered
with 50 ng/ml DNP-HSA for 20 min. Fig. 3 shows that
anti-CD63 pretreatment induced a 46% inhibition of
Fc
 
 
 
RI-induced serotonin release compared with the isotype
control in adherent cells (P 
 
  
 
0.05). In contrast, anti-CD63
had no significant effect on cells in suspension. To ensure
that the lower release observed with adherent cells incu-
bated with anti-CD63 was not due to the detachment of
cells by anti-CD63, we verified that [
 
3
 
H]serotonin incorpo-
ration was identical in cells treated with isotype control and
cells treated with anti-CD63 (unpublished data). We also
verified that the lack of effect of anti-CD63 on cells in sus-
pension was not due to a loss of the epitope due to
trypsinization by performing anti-CD63 staining and flow
cytometric analysis of cells detached with EDTA or with
trypsin. The mean fluorescent intensity of CD63 expression
was 87.00 (arbitrary units) for cells detached with 0.02%
EDTA alone and 110.51 for cells detached with 0.05%
trypsin and EDTA (mean of 
 
n
 
 
 
 
 
 3). Note that RBL cells, in
contrast to immature MC, adhere spontaneously to many
surfaces, probably as a result of the activating mutation of
c-Kit they harbor.
These results suggested that the inhibitory effect of anti-
CD63 on MC could be mediated via an effect on MC adhe-
sion to fibronectin and vitronectin present in FCS. To spe-
cifically assess the effect of anti-CD63 on integrin-mediated
adhesion, we analyzed RBL adhesion to various ECM pro-
teins. Fibronectin and vitronectin enhance MC degranula-
tion, whereas fibrinogen provides a strong attachment factor
for MCs, but has not been shown to enhance mast cell de-
granulation (11). Cells were incubated with anti-CD63 or
IgG1 control (10 
 
 
 
g/ml) and then plated in dishes that had
been coated with one of these ECM proteins or left un-
coated, and blocked with BSA. After a 30-min incubation at
37
 
 
 
C, nonadherent cells were removed by washing and cell
adherence was determined. Fig. 4 A shows that anti-CD63
strongly inhibited adhesion of RBL to fibronectin and vi-
tronectin in a dose-dependent manner compared with the
isotype control. Anti-CD63–mediated inhibition of adhe-
sion to fibronectin was of the same order of magnitude as in-
hibition by the corresponding anti-integrin Abs anti-
 
 
 
5 and
anti-
 
 
 
1 used together. However, anti-CD63–mediated inhi-
bition of adhesion to vitronectin was stronger than inhibi-
tion by the corresponding anti-integrin anti-
 
 
 
3, possibly be-
cause of the expression of other vitronectin binding integrins
besides 
 
 
 
v
 
 
 
3 integrin in MC. In contrast to the inhibition of
adhesion to fibronectin and vitronectin, adhesion to fibrino-
gen was not affected by anti-CD63.
These experiments showed that anti-CD63 was capable
of inhibiting adhesion to fibronectin and vitronectin, both of
which are known to enhance degranulation. In contrast,
anti-CD63 had no effect on adhesion to fibrinogen, which is
not known to affect degranulation. This suggested that anti-
CD63 targets a mechanism that is responsible for modulation
of degranulation by adhesion to these ECM proteins. If this
was correct, then anti-CD63 should inhibit degranulation of
cells adhering to fibronectin and vitronectin, but not fibrino-
gen. To test this, we compared the capacity of anti-CD63 to
inhibit degranulation in cells adhering to these ECM
proteins. Fig. 4 B shows a strong suppressive effect of anti-
CD63 on degranulation when cells were attached to fibronec-
tin and vitronectin, although the effect was nonsignificant
when cells were attached to fibrinogen or plated in uncoated
wells. Note that we did not observe the enhancement of de-
granulation under adherent conditions published previously
Figure 3. Anti-CD63 suppresses degranulation in adherent cells, 
but not in cells in suspension. The capacity of anti-CD63 (12A10 mAb) 
to inhibit Fc RI-induced degranulation was compared in RBL cells that 
were stimulated either in suspension or adherent (mean   SEM of six 
experiments with duplicate samples). * P   0.0051. Cells were loaded with 
[3H]serotonin and anti-DNP–IgE and triggered, or not, with 50 ng/ml 
DNP-HSA for 20 min.JEM VOL. 201, February 7, 2005 389
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(9, 10; Figs. 3 and 4 B). This may be due in part to technical
reasons. The RBL cells we used adhere spontaneously to tis-
sue culture plates and polypropylene tubes, and constant agi-
tation had to be used to minimize adhesion. Together these
results show that anti-CD63 inhibits both adhesion to fi-
bronectin and vitronectin, and degranulation of MC grown
on these substrates while leaving the degranulation of non-
adherent MC intact.
Anti-CD63 leaves Fc RI-induced global tyrosine 
phosphorylation and Ca2  mobilization intact
The next question was to determine the mechanism of the
dual inhibition of adhesion and degranulation. Therefore,
we systematically tested the effect of anti-CD63 on various
steps of the Fc RI signaling pathways. We first assessed the
effect of anti-CD63 on the first event observed after Fc RI
aggregation, which is activation of PTKs and subsequent ty-
rosine phosphorylation of numerous substrates. Global tyro-
sine phosphorylation was measured by blotting of total cell
lysates prepared after 1 to 20 min of triggering with antigen
(50 ng/ml DNP-HSA) in adherent cells pretreated with
12A10 (10  g/ml) or vehicle. Fig. 5 A shows that Fc RI ag-
gregation-induced tyrosine phosphorylation was unaffected
by anti-CD63. Therefore, it is unlikely that anti-CD63 in-
hibits activation of PTKs, such as Lyn, which is responsible
for phosphorylation of the Fc RI   and   chains and for ac-
tivation of numerous molecules such as Syk, LAT, or SLP-
76. However, this does not rule out that anti-CD63 could
inhibit directly or indirectly the tyrosine phosphorylation of
discrete signaling molecules downstream. To confirm that
Lyn activity was not affected by anti-CD63, we tested the
effect of anti-CD63 on Ca2  mobilization, a signal depen-
dent on Lyn (29). Fc RI-induced Ca2  mobilization was
measured with fura-2 in adherent cells. There was no signif-
icant difference between the average Ca2  traces of cells pre-
treated with IgG1 and those of cells pretreated with the anti-
CD63 mAb 12A10 (Fig. 5 B). We verified in parallel (same
conditions) that anti-CD63 preincubation did suppress de-
granulation (unpublished data). Note that the absence of ef-
fect of the anti-CD63 on tyrosine phosphorylation and Ca2 
mobilization essentially rules out the possibility that the inhi-
Figure 4. Anti-CD63 potently suppresses both degranulation and 
adhesion on fibronectin and vitronectin, but not fibrinogen. (A) The 
capacity of anti-CD63 to inhibit adhesion to fibronectin, vitronectin, and 
fibrinogen was compared in RBL cells preincubated with control IgG1 or 
anti-CD63 (12A10) and plated for 30 min at 37 C on 96-well plates coated 
with fibronectin, vitronectin, or fibrinogen. Adhesion was quantified by 
crystal violet uptake measured by spectrophotometry at 570 nm in cell 
lysates and is expressed in arbitrary units after subtracting the value for 
adhesion to uncoated wells. Results are expressed as mean   SEM of 
seven samples (fibronectin) or six samples (vitronectin and fibrinogen). 
*P   0.05 of anti-CD63–treated cells versus IgG1-treated cells. Antibodies 
directed against the  5 and  1 chain of  1 integrins or against  3 inte-
grins were used as positive controls. (B) The capacity of anti-CD63 (12A10 
mAb at 10  g/ml) to inhibit Fc RI-induced serotonin release was compared 
in anti-DNP IgE-loaded RBL cells that were grown for 16 h in the absence 
of FCS on uncoated wells or surfaces coated with fibronectin, vitronectin, 
or fibrinogen. All wells were blocked with 2% BSA solution before adding 
cells. Shown are mean percentage of serotonin release   SEM from 12 
samples (fibronectin), 10 samples (vitronectin and fibrinogen), and 8 
samples (uncoated). * P   0.05.ANTI-CD63 SUPPRESSES ALLERGIC REACTIONS | Kraft et al. 390
bition could be due to cocrosslinking with the inhibitory re-
ceptor Fc RIIB (30).
Because anti-CD63 did not affect the synthesis of arachi-
donic acid metabolites (Fig. 1 C), which is induced by MAP
kinase-triggered PLA2 activation (13–15), we hypothesized
that the MAP kinase pathway was insensitive to anti-CD63.
We used phosphorylation of the p42 and p44 MAP kinase
(Erk1 and Erk2) as a read-out. Adherent cells were pre-
treated with 10  g/ml anti-CD63 and triggered with 50 ng/
ml DNP-HSA for 2 and 10 min. Indeed, Fc RI-induced
phosphorylation of p42 and p44 MAP kinase was readily de-
tectable but not affected by anti-CD63 (unpublished data).
Based on these results we hypothesized that anti-CD63
might specifically affect Ca2 -independent signals that are
not part of the pathway controlled by Lyn.
Anti-CD63 inhibits Gab2-dependent signal transduction, 
which results in diminished activity of the Ca2 -independent 
PKC  isoform in adherent cells
Degranulation is controlled by a newly described pathway
that involves a complex organized by the Gab2 adaptor (16,
17). This complex is known to contain PI3K, which is re-
sponsible for generating PtdIns-3,4,5-trisP (PIP3), a mem-
brane lipid that binds pleckstrin homology (PH) domains
and targets PH domain–containing proteins to the plasma
membrane. Comparable Gab2 signaling complexes exist also
in   integrin signaling (31). We hypothesized that the inhib-
itory effect of anti-CD63 might be due to the targeting of
these Gab2 complexes. To test this hypothesis, we analyzed
the effect of anti-CD63 on Gab2 activation. Upon Fc RI
aggregation, Gab2 is tyrosine phosphorylated and recruited
to the plasma membrane (16, 17, 32). We analyzed tyrosine
phosphorylation of Gab2 on anti-Gab2 immunoprecipitates
by antiphosphotyrosine blot (Fig. 6 A, representative of
three similar experiments). We observed an inhibition of
Fc RI-induced tyrosine phosphorylation by anti-CD63 (10
 g/ml) at early time points. This is confirmed by the disap-
pearance with anti-CD63 pretreatment of the mobility shift
observed after Fc RI triggering on the anti-Gab2 blot (Fig.
6 A, right). This mobility shift has been attributed to the
phosphorylation of Gab2. We then predicted that Fc RI ag-
gregation-induced translocation of Gab2 would be inhibited
by anti-CD63, whereas that of Syk, which is dependent
on the Lyn-mediated tyrosine phosphorylation of Fc RI 
would not. Indeed, Gab2 translocation to the plasma mem-
brane induced by Fc RI aggregation was decreased after
anti-CD63 pretreatment (10  g/ml), although Syk translo-
cation was unaffected (Fig. 6 B representative of three similar
experiments). The lack of effect of anti-CD63 on Syk trans-
location confirms our findings that the Lyn pathway is unaf-
fected by anti-CD63 (Fig. 5).
To confirm that anti-CD63 targets Gab2 signaling, we
analyzed signaling molecules downstream of Gab2. PI3-
kinase–dependent kinase-1 (PDK-1) is an effector of Gab2
and participates in the activation of the protein kinase Akt/
PKB, another component of Fc RI signaling (33). Akt is ac-
tivated by phosphorylation by PDK-1 after recruitment to
the plasma membrane via the binding of its PH domain to
PIP3 (34, 35). We assessed the effect of anti-CD63 on mem-
brane translocation and phosphorylation of Akt after Fc RI
aggregation. As expected, anti-CD63 (10  g/ml) suppressed
membrane translocation of Akt (Fig. 6 B representative of
three similar experiments). A strong inhibition of Akt serine
phosphorylation, which is commonly used as a marker for
PIP3 production, was detected as well (Fig. 6 C representa-
tive of three similar experiments). Anti-CD63 even inhib-
ited Akt phosphorylation in resting adherent cells. This is in
line with our observation that Gab2 translocation, which is
also dependent on PH domain–mediated binding to mem-
brane phospholipids (36), was suppressed below basal levels
by anti-CD63 (Fig. 6 B). Akt and PI3K play a prominent
role in fibronectin- and vitronectin-induced   integrin sig-
Figure 5. Anti-CD63 leaves Fc RI-induced global tyrosine phos-
phorylation and Ca2  mobilization intact. (A) Whole cell lysates of
unstimulated (0 min) and Fc RI-triggered (DNP-HSA) RBL-2H3 cells prein-
cubated with 12A10 ( ) or vehicle ( ) were blotted with the anti-
phosphotyrosine antibody 4G10. Cells were stimulated under adherent 
conditions. The data are representative of four experiments. (B) RBL-2H3 
cell were preincubated with 10  g/ml of 12A10 or control IgG1 and loaded 
with fura 2-AM. Ca2  mobilization induced by Fc RI triggering (50 ng/ml 
DNP-HSA) was measured in a spectrofluorometer and expressed as the 
ratio of emission with excitation at 340 and 380 nm. Shown are average 
traces from 11 for IgG1 (black lines) and 10 experiments for anti-CD63 
(gray lines). Ratios (R) at each time point after addition of DNP-HSA were 
normalized to the baseline ratio during the first 60 s of recording (R0).JEM VOL. 201, February 7, 2005 391
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naling and function as well (37–40). Thus, this suppression
of basal Akt activation suggests that anti-CD63 inhibits   in-
tegrin signals. A second function of PDK-1 is to activate
PKC , a novel, Ca2 -independent PKC isoform that is crit-
ical for degranulation in RBL cells (28), and which partici-
pates in the   integrin signaling pathways (41). To investi-
gate the effect of anti-CD63 on Fc RI-induced activity of
PKC , we stimulated adherent RBL cells by Fc RI cross-
linking and assessed PKC activity by in vitro kinase assay us-
ing myelin basic protein (MBP) as a substrate. PKC  kinase
activity was induced and this activation was suppressed by
preincubation with 12A10 in adherent cells (Fig. 6 D, top,
representative of six similar experiments). However, when
the experiment was performed on cells in suspension, PKC 
was activated by Fc RI effectively, but this activation was
not inhibited by anti-CD63 (Fig. 6 D, bottom, representa-
tive of three similar experiments). As an additional control
we chose to analyze another novel PKC isoform, PKC ,
which is activated upon Fc RI triggering, but does not seem
to play a role in degranulation. As expected, PKC  kinase
activity was induced by Fc RI but was not affected by anti-
CD63 pretreatment (unpublished data). The lack of sensitiv-
ity of PKC , a negative regulator of PLA2 (42, 43), is in
agreement with the insensitivity of arachidonic acid synthesis
induction to anti-CD63 (Fig. 1 C).
All together, these results demonstrate that the anti-
CD63 targets a Ca2 -independent signaling pathway charac-
terized by Gab2 and PKC , which controls degranulation
and is also essential in signaling by   integrins.
Anti-CD63 suppresses passive cutaneous anaphylaxis in vivo
Suppression of both MC adhesion and MC degranulation
could represent a method of treating MC-mediated diseases.
For this reason, we next assessed the efficacy of anti-CD63
Figure 6. Anti-CD63 inhibits Gab2-dependent signal transduction, 
which results in diminished activity of the Ca2 -independent PKC  
isoform in adherent cells. (A) Adherent RBL-2H3 cells were preincubated 
with 12A10 or left untreated. They were then either left unstimulated (nil) 
or stimulated by Fc RI cross-linking (DNP). Cells were then lysed and Gab2 
was immunoprecipitated. Immunoprecipitates were blotted with anti-
phosphotyrosine mAb 4G10 (left) or with anti-Gab2 (right). These data are 
representative of three experiments. (B) Adherent RBL-2H3 cells were 
stimulated as described for A for 2 min. After lysis, plasma membrane 
fractions were separated from cytosolic fractions and subjected to immu-
noblotting with anti-Akt, anti-Gab2, and anti-Syk antibodies. These data 
are representative of three experiments. (C) Adherent RBL-2H3 cells were 
stimulated as described for A. Whole cell lysates were immunoblotted with 
anti-phospho–Akt (left) and anti-Akt (right) to confirm that equal 
amounts were loaded. These data are representative of three experiments. 
(D) RBL-2H3 cells, either adherent (top) or in suspension (bottom) were 
preincubated with 12A10, and either left unstimulated (nil) or stimulated 
by Fc RI cross-linking for 3 min (DNP). Cells were then lysed and PKC  
was immunoprecipitated. Immunoprecipitates were subjected to in vitro 
kinase assay using MBP as substrate (left). The immunoprecipitates were 
blotted with anti-PKC  to confirm that equal amounts of PKC  were im-
munoprecipitated (middle). A densitometric analysis of the MBP band in in 
vitro kinase assays was performed (right) and the results are expressed as 
mean   SEM of percent increase after Fc RI aggregation compared with 
baseline activity in six (adherent) or three (suspension) experiments. 
*P   0.0277 of anti-CD63–treated cells versus vehicle-treated cells.ANTI-CD63 SUPPRESSES ALLERGIC REACTIONS | Kraft et al. 392
in suppressing allergic reactions involving normal tissue–resi-
dent MCs in vivo. In a passive cutaneous anaphylaxis (PCA)
model, antigen-specific IgE is injected into the back skin of
rats. An immediate-type allergic reaction is induced by in-
jection of antigen and Evan’s Blue dye. MC activation
through Fc RI in PCA results in the release of several vaso-
active substances, which increases vascular permeability. This
property can be quantified by local accumulation of the
Evan’s Blue dye leaving the vessels in the area of previous
IgE injection. These results are expressed as micrograms of
Evan’s Blue dye extracted from tissue biopsies. As shown in
Fig. 7, coinjection of anti-CD63 mAb significantly inhibited
IgE-dependent PCA reactions. Importantly, the extent of
inhibition of IgE-mediated anaphylaxis with 58.6% (10 ng
anti-DNP IgE) and 57.3% suppression (25 ng anti-DNP
IgE) was comparable to the highest levels achieved in vitro.
These data demonstrate that anti-CD63 can suppress allergic
reactions in vivo.
DISCUSSION
We have generated mAbs that were selected based on their
capacity to inhibit Fc RI-induced MC degranulation in
vitro (Fig. 1, A and B). Two of these mAbs recognize
CD63, a tetraspanin that can associate with   integrins (22,
23, 25, 26, 44), the cell surface proteins responsible for adhe-
sion to ECM proteins (Fig. 2). These mAbs inhibit degranu-
lation of adherent MC but not of nonadherent MC (Fig. 3).
In addition, these mAbs inhibit MC adhesion to fibronectin
and vitronectin, the ECM proteins that amplify MC degran-
ulation (9–11) but not to fibrinogen, which has no known
effect on degranulation (Fig. 4). Furthermore anti-CD63 in-
hibits degranulation of MC adhering to fibronectin and vi-
tronectin, but not of MC adhering to fibrinogen (Fig. 4). In
terms of the molecular mechanism of this inhibition, we
show that anti-CD63 inhibits the Fc RI-mediated PI3K–
Gab2–PKC  pathway that leads to degranulation (Fig. 6),
whereas the Lyn–Ca2  mobilization pathway is unaffected
(Fig. 5). Anti-CD63 is also inhibitory when tested in an ani-
mal model of allergic reactions, suggesting that it has poten-
tial therapeutic value (Fig. 7).
Adhesion has been shown to modulate Fc RI-induced
degranulation in several studies (9–11). However the molec-
ular events responsible for the crosstalk between adhesion and
degranulation are not well understood. Please note that for
the sake of simplicity we use the term adhesion for a variety
of complex processes that include static adhesion (i.e., the
binding of integrins to substrates and cell attachment) and dy-
namic adhesion (e.g., integrin-mediated spreading of cells to
ECM surfaces, adhesion strengthening upon shear flow). It is
likely that tetraspanins play a role in dynamic adhesion. For
example, CD81 is involved in  4 1 and  5 1 integrin–medi-
ated adhesion strengthening in monocytes and B cells under
shear flow (45). In fact the supportive effect of adhesion for
MC degranulation has been attributed to cell spreading (9).
A role for the focal adhesion kinase FAK in adhesion-
enhanced degranulation has also been proposed (46, 47). How-
ever, Fc RI function is normal in FAK-deficient MC (48).
Therefore, it is unlikely that FAK plays a major role in am-
plification of degranulation by adhesion.
Another pathway involved in integrin-mediated adhe-
sion that could potentially modulate degranulation involves
the adaptor Fyn-binding protein (FYB/SLAP–130/ADAP).
In MCs, FYB enhances adhesion to fibronectin and media-
tor release after Fc RI aggregation (49). However, FYB am-
plifies degranulation in nonadherent as well as adherent cells
(49). In preliminary experiments we assessed Fc RI-medi-
ated tyrosine phosphorylation of FYB and found that it was
not affected by anti-CD63 (unpublished data). Therefore,
the mechanism targeted by anti-CD63 is probably different
from the one involving FYB.
Our results show that anti-CD63 inhibits the Gab2–
PI3K–PKC  signaling pathway that is common to degranu-
lation and adhesion. These data shed new light on the mo-
lecular connections between Fc RI-mediated degranulation
and adhesion. We propose that membrane complexes con-
taining CD63 control MC adhesion and regulate Fc RI-
induced degranulation via a shared signaling pathway. Fig. 8
shows a schematic representation of this pathway. Besides
Lyn, Fc RI aggregation induces the activation of Fyn in
BMMC. In RBL cells, Fyn expression is very low, thus an-
other PTK could play the role of Fyn (16, 32). This event,
along with Syk activation, promotes the formation of a com-
plex that involves PI3K and the adaptor Gab2. Gab2 is nec-
essary for PI3K activation, and, in turn, the PI3K product
PI3,4,5P3 (PIP3) promotes the recruitment of Gab2 to the
plasma membrane via its PH domain. PI3K products also
promote the recruitment and activation of PDK-1 and Akt,
which is then activated by phosphorylation by PDK-1.
PDK-1 also activates PKC  (16), which results in degranula-
tion. Signaling by   integrins involves the generation of
Figure 7. Anti-CD63 suppresses passive cutaneous anaphylaxis 
reactions in rats. Rats were sensitized intradermally with 10 or 25 ng 
anti-DNP IgE along with 50  g 12A10 or control IgG1 in duplicate sites. 
24 h later PCA was induced by i.v. injection of DNP-HSA along with Evan’s 
Blue. The skin sites were excised, Evan’s Blue was extracted, and quantified 
by absorbance at 610 nm. The results are expressed as mean   SEM of  g 
Evan’s Blue (four duplicate experiments).JEM VOL. 201, February 7, 2005 393
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comparable Gab2-organized complexes (31) leading to Akt
and PKC  activation (37–41). Adhesion could amplify
Fc RI-induced degranulation by increasing the amount of
activated Gab2, PI3K, and PKC  for the Fc RI-induced
signaling pathways. This could be accomplished, e.g., if ad-
hesion brought together the plasma membrane micro-
domains that contain Fc RI with those that contain CD63,
its associated integrins and their signaling machinery.
How could anti-CD63 binding to MC exert its inhibi-
tory effect? In CD63 integrin-containing membrane com-
plexes mAb binding to CD63 could either generate an in-
hibitory signal or block a positive signal for adhesion and
Fc RI-induced aggregation. The first possibility would be
comparable to the mechanism used by ITIM-containing in-
hibitory receptors, which upon cross-linking with Fc RI
suppress antigen receptor signaling through activation of an
inositol phosphatase (18). This seems unlikely since CD63
does not contain an ITIM motif and anti-CD63 did not di-
minish Ca2  mobilization, which would be observed if an
inositol phosphatase such as SHIP was activated by an ITIM
(30). Although we cannot exclude that unknown inhibitory
signals are activated by anti-CD63, our data provide no sup-
port for this hypothesis.
The second possibility (inhibition of a positive signal) is
supported by our observation that Gab2 membrane translo-
cation and Akt phosphorylation are suppressed by anti-
CD63 in adherent cells even when unstimulated (Fig. 6,
A–C). These data suggest that in unstimulated cells, adher-
ence to specific ECM proteins provides a positive signal that
can be inhibited by anti-CD63. The inhibition of this posi-
tive signal could be generated by at least three different
mechanisms (or a combination of them).
First, anti-CD63 could sterically hinder integrin binding
to their ECM substrates. This would have a direct effect on
adhesion. In this scenario, adhesion would first be inhibited.
This steric inhibition would then suppress the adhesion-
mediated positive signals involving the Gab2–PI3K pathway
with a resulting negative impact on Fc RI-mediated degran-
ulation (Fig. 8, MECHANISM 1).
Second, anti-CD63 could act by generally disrupting the
membrane complexes containing CD63, associated integrins
and tetraspanins and associated signaling components. This
uncoupling of integrins from their signaling molecules
would lead to the inhibition of the adhesion-mediated acti-
vation of the Gab2–PI3K pathway. Impairment of this
pathway would then lead to a decrease in adhesion and sub-
sequently to the inhibition of degranulation (Fig. 8, MECH-
ANISM 2).
Third, anti-CD63 could sequester CD63 and its associ-
ated signaling molecules (Fig. 8, MECHANISM 3). Our
data on Gab2 and Akt show that anti-CD63 inhibits PIP3
production or an upstream signal. PtdIns-4 kinase (PI4K) as-
sociates with CD63 and its sequestration could have such an
effect (50). PI4K produces PtdIns-4–P (PI4P), which can be
further phosphorylated to PtdIns-4,5P2 (PI4,5P2) by PIP5K.
Recently our laboratory has demonstrated the importance of
PIP5K in generating PI4,5P2 and in modulating PI3K acti-
vation (51). PI4,5P2 is the substrate of PI3Ks. Therefore, lo-
cal sequestration of PI4K could inhibit specific pools of
PI4,5P2 and lead to specific inhibition of selective PI3K iso-
forms (for example the p110  isoform, see below). This in
turn would inhibit the Gab2 pathway and lead to the inhibi-
tion of adhesion and degranulation. Note that the PI3K iso-
form present in the Gab2-organized complex most likely
Figure 8. Schematic representation of our model for the mechanism 
of anti-CD63 inhibition. The Lyn–Ca2 -dependent signaling pathway for 
degranulation is shown in gray. The Ca2 -independent PI3K–Gab2–PKC  
signaling pathway shared with the integrin–tetraspanin complex is shown 
in black and yellow. Mechanism 1 (steric hindrance of integrin binding to 
their ECM substrates) is represented in green. Mechanism 2 (general dis-
ruption of the membrane complexes containing CD63) is represented in 
blue. Mechanism 3 (sequestration of PI4K) is represented in red.ANTI-CD63 SUPPRESSES ALLERGIC REACTIONS | Kraft et al. 394
differs from the one responsible for the membrane targeting
of various signaling molecules in the Lyn–Ca2  mobilization
pathway, such as Btk or Grb2 (12). Studies showing that
antibodies against the p110  isoform of PI3K inhibit de-
granulation without affecting Ca2  mobilization, whereas
antibodies against the p110  and p110  isoforms inhibit
degranulation and Ca2  mobilization (52, 53) suggest that
p110  is part of the degranulation pathway, whereas p110 
and p110  are involved in the Lyn–Ca2  mobilization path-
way. In summary, we propose that Fc RI-induced degranu-
lation is regulated by adhesion-controlled CD63–integrin
membrane complexes whose signaling pathways overlap with
those of Fc RI-induced degranulation.
A number of recent studies have demonstrated the effi-
cacy of mAbs as therapeutic tools. Using a rodent model of
allergic diseases, we show that anti-CD63 mediated inhibi-
tion of MC adhesion and degranulation works in vivo. In
the field of allergy, humanized anti-IgE Abs have demon-
strated good efficacy and good tolerance. Two recent clinical
studies of anti- 4 integrin Ab, one in multiple sclerosis, and
one in Crohn’s disease (54–56), have shown the therapeutic
value and feasibility of interfering with integrin function.
Given their capacity to interfere with multiple MC func-
tions, our anti-CD63 mAbs may have therapeutic potential
in diseases where MCs are important such as allergic diseases,
rheumatoid arthritis, and multiple sclerosis (1, 3).
MATERIALS AND METHODS
Cell culture, reagents, and antibodies. RBL-2H3 and U-937 cells
were maintained as described previously (19). Anti-DNP IgE (clone SPE-7)
was from Sigma-Aldrich; anti- 1 integrin–CD29 (clone Ha2/5), anti- 5
integrin–CD49e (clone HM 5-1), and anti- 3 integrin–CD61 (clone
2C9.G2) from BD Biosciences; anti-PKC  (C-17) and anti-Syk (N-19)
from Santa Cruz Biotechnology, Inc.; anti-Gab2 from Upstate Biotechnol-
ogy; anti-phospho–Akt (Ser473) and anti-Akt from Cell Signaling.
Production of mAbs. Hybridomas against RBL were generated as de-
scribed previously (19). Two hybridomas (7A6 and 12A10) were selected
for analysis. Their isotype (IgG1) was determined with a mouse IgG isotyp-
ing kit (Amersham Biosciences).
Serotonin release assays. Assays were performed as described in reference
19 with the following modifications. For cells in suspension, the cells were
detached after IgE and serotonin loading and incubated with Abs in suspen-
sion. Stimulation was performed in BSA-coated tubes under continuous slow
rotation. For cells grown on ECM proteins, the cells were attached to ECM
protein–coated wells for 16 h as described below for adhesion assays.
LTC4 production.  The assay was performed as described in reference 19. 
Cloning and expression of rat CD63.  Total RNA was isolated from
RBL cells using RNAzol B (Tel-Test Inc.) and cDNA was obtained using
Omniscript reverse transcriptase (QIAGEN). NH2-terminal FLAG-tagged
CD63 was amplified from the cDNA with Advantage cDNA polymerase
(Clontech Laboratories, Inc.) and the following primers: forward 5 -CAG-
AATTCCCACCATGGGCGACTACAAGGACGACGATGACAAGGC-
GGTGGAAGGAGGAATGAAGTGTG-3 ; reverse 5 -CACAAGCTTGG-
GCTACATTACTTCGTAGCCACTCC-3 . The 762-bp PCR product
was subcloned into the pBJ1neo expression vector. DNA (10  g) was elec-
troporated in U937 cells (950  F; 300 V) and selection was initiated 48 h later
with 0.6  g/ml G418 (Invitrogen). Transfected cells were stained with 7A6
and 12A10 and analyzed by flow cytometry.
Immunoblotting and immunoprecipitation. RBL loaded with anti-
DNP IgE for 16 h in the presence of 10% FCS under adherent conditions were
preincubated with 12A10 or 7A6 (10  g/ml for 30 min). Fc RI aggregation
was performed as for serotonin release assays. For analysis of PKC  activity un-
der nonadherent conditions, cells were detached using 0.05% trypsin after load-
ing with IgE. Preincubation with 12A10 and Fc RI aggregation were per-
formed in polypropylene tubes under continuous slow rotation. Cells were
lyzed and lysates were blotted and precipitated according to standard proce-
dures. For separation of membrane and cytosolic fractions cells were scraped in
homogenization buffer (25 mM Hepes, pH 7.4, 5 mM EGTA, 50 mM NaF,
and a protease inhibitor cocktail). After homogenization in a Dounce homoge-
nizer, cell debris was removed by centrifugation (800 g for 5 min at 4 C) and
the supernatant was centrifuged to pellet membranes (250,000 g for 30 min at
4 C). The pellet was resuspended in 200  l homogenization buffer and ana-
lyzed by SDS-PAGE and Western blotting as in reference 57.
Adhesion assays. 96-well tissue culture plates were coated with 10  g/ml
fibronectin, vitronectin, or fibrinogen (all Sigma-Aldrich) in PBS for 16 h at
room temperature and blocked with 2% BSA in Ca2 /Mg2 -free PBS for
2 h at 37 C. RBL were starved in culture medium without FCS for 16 h.
They were then detached and incubated in Eagle's minimal essential medium
containing 0.1% BSA (without FCS) with Abs at 10–40  g/ml for 1 h at
37 C. After washing the cells were incubated in the coated wells for 30 min
at 37 C. They were then washed and fixed with 2.5% formaldehyde. After
washing with PBS, staining was performed for 1 h at room temperature with
0.1% crystal violet and the cells were lysed in 10% acetic acid. Adhesion was
quantified by reading absorption of the incorporated dye at 570 nm.
Ca2  measurements. RBL were seeded onto 10 mm glass coverslips at
0.4   106/ml in culture medium with 0.2  g/ml anti-DNP IgE for 16 h.
Cells were then loaded with fura-2 a.m. ester as described in reference 26 and
with 10  g/ml Ab for 45 min at 37 C. The coverslips were placed into a
holding device inside the cuvette of a Deltascan spectrofluorometer (PTI) and
analysis was performed as described previously (24). 340:380 ratios (R) were
normalized to the average baseline ratios during the first 60 s of recording
(R0). The area under the curve for each experiment was calculated and an
unpaired t test was performed using Prism4 software (GraphPad Software).
PKC  kinase assays. For assessment of PKC  kinase activity, anti-PKC 
immunoprecipitates from 5   106 RBL-2H3 cells were incubated in 20  l
kinase buffer (57) plus 10  l substrate mix containing 1  g MBP (Sigma-
Aldrich), 50  M ATP, and 10  Ci [ 32P]-ATP (NEN Life Science Prod-
ucts) for 30 min at room temperature. Reactions were stopped with one vol-
ume of 2  SDS sample buffer and samples were separated by SDS-PAGE.
Analysis of phosphorylated bands was performed on a Molecular Imager
(Bio-Rad Laboratories). Immunoprecipitates were analyzed for equal amounts
of the PKC  using immunoblots with anti-PKC  antibodies.
Passive cutaneous anaphylaxis (PCA). PCA assays were performed as
described previously (19).
Statistical analysis. Statistical analysis was performed with the Mann-
Whitney test for ungrouped variables and the Wilcoxon test for grouped
variables using StatView 5.0.1 software (SAS Institute Inc.).
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